Akorn-Strides, LLC Announces FDA Approvals for Famotidine Injection USP, 20 mg/2mL Single-Dose Vials and Famotidine ... (Business Wire via Yahoo! Finance)
BUFFALO GROVE, Ill.----Akorn-Strides, LLC today announced the approvals of two ANDAs for Famotidine Injection USP, 20 mg/2mL Single-Dose Vials and 40 mg/4mL & 200 mg/20mL Multiple-Dose Vials.

FDA Grants Priority Review For MediQuest's Drug Application To Treat Raynaud's Disease (Medical News Today)
MediQuest Therapeutics Inc. announced that it has been granted priority review status from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for MQX-503, a topical formulation designed to treat Raynaud's Disease. A priority review provides the opportunity for an approvability decision by the FDA within six months instead of the standard ten months or more.